Perrigo passes US FDA's final approval for generic Estrace Cream
25 January 2018 -

Healthcare company Perrigo Company plc (NYSE:PRGO)(TASE:PRGO) revealed on Wednesday the receipt of final approval from the US Food and Drug Administration for the generic version of Estrace Cream (estradiol vaginal cream, USP, 0.01%) for vulvar and vaginal atrophy due to menopause.

With an expected launch in the Q2 of this year, the Estrace Cream will be marketed by the company's partner, Impax Laboratories Inc (NASDAQ:IPXL).

According to the company, Estrace Cream is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.

For the last 12 months, the market sales of Estrace Cream were approximately USD457m, according to IMS Health.